UROGEN PHARMA LTD's ticker is URGN and the CUSIP is M96088105. A total of 103 filers reported holding UROGEN PHARMA LTD in Q3 2023. The put-call ratio across all filers is 0.62 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $376,355 | +78.2% | 26,864 | +31.6% | 0.00% | – |
| Q2 2023 | $211,202 | +4.6% | 20,406 | -11.9% | 0.00% | – |
| Q1 2022 | $202,000 | -11.8% | 23,152 | -3.8% | 0.00% | – |
| Q4 2021 | $229,000 | -44.3% | 24,064 | -1.4% | 0.00% | -100.0% |
| Q3 2021 | $411,000 | +12.6% | 24,408 | +2.1% | 0.00% | – |
| Q2 2021 | $365,000 | -29.5% | 23,903 | -10.1% | 0.00% | -100.0% |
| Q1 2021 | $518,000 | +0.4% | 26,578 | -7.2% | 0.00% | 0.0% |
| Q4 2020 | $516,000 | +4.9% | 28,648 | +12.3% | 0.00% | 0.0% |
| Q3 2020 | $492,000 | -35.3% | 25,517 | -12.3% | 0.00% | 0.0% |
| Q2 2020 | $760,000 | +81.0% | 29,087 | +23.5% | 0.00% | 0.0% |
| Q1 2020 | $420,000 | -46.2% | 23,548 | +0.6% | 0.00% | 0.0% |
| Q4 2019 | $781,000 | +49.0% | 23,405 | +6.3% | 0.00% | 0.0% |
| Q3 2019 | $524,000 | -30.9% | 22,010 | +4.4% | 0.00% | 0.0% |
| Q2 2019 | $758,000 | – | 21,079 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 2,620,545 | $36,713,835 | 6.69% |
| Wildcat Capital Management, LLC | 495,606 | $6,943,440 | 2.79% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 508,883 | $7,129,451 | 2.16% |
| Opaleye Management Inc. | 320,000 | $4,483,200 | 1.46% |
| AlphaCentric Advisors LLC | 165,000 | $2,311,650 | 1.31% |
| Soleus Capital Management, L.P. | 372,000 | $5,211,720 | 0.48% |
| EAM Investors, LLC | 170,523 | $2,389,027 | 0.46% |
| RA Capital Management | 1,483,697 | $20,786,595 | 0.41% |
| Parkman Healthcare Partners LLC | 145,311 | $2,035,807 | 0.37% |
| MENORA MIVTACHIM HOLDINGS LTD. | 2,303,031 | $32,265,464 | 0.29% |